The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

Chest

Volumn 118, Issue 1, 2000, Pages 146-155

  Ibrahim, Emad H ^a   Sherman, Glenda ^a   Ward, Suzanne ^a   Fraser, Victoria J ^a   Kollef, Marin H ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

Antibiotics; Bacteremia; Bloodstream infections; Candida species; Enterococci; Intensive care; Outcomes; Resistance; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; VANCOMYCIN;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; CANDIDA; CONTROLLED STUDY; DISEASE COURSE; ENTEROCOCCUS; FEMALE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STAPHYLOCOCCUS; TEACHING HOSPITAL; TREATMENT OUTCOME;

EID: 0141610906     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.118.1.146     Document Type: Article

References (48)

1. Linden PK. Clinical implications of nosocomial Gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998; 104:24S-33S
2. Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379-386
3. Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: A case-control and molecular epidemiologic investigation. J Infect Dis 1996; 174:529-536
4. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24:584-602
5. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: Analysis of 189 episodes. Arch Intern Med 1996; 156:2121-2126
6. Caballero-Granado FJ, Cisneros JM, Luque R, et al. Comparative study of bacteremias caused by Enterococcus spp. with and without high-level resistance to gentamicin. J Clin Microbiol 1998; 36:520-525
7. Bryan CS, Reynolds KL, Brenner ER. Analysis of 1186 episodes of Gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983; 5:629-638
8. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-590
9. Mainous MR, Lipsett PA, O'Brien M. Enterococcal bacteremia in the surgical intensive care unit: Does vancomycin resistance affect mortality? Arch Surg 1997; 132:76-81
10. Lucas GM, Lechtzin N, Puryear DW, et al. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: Comparison of clinical features and outcomes. Clin Infect Dis 1998; 26:1127-1133
11. Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: Impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996; 23:255-259
12. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474
13. Ascar JF. Consequences of bacterial resistance to antibiotics in medical practice. Clin Infect Dis 1997; 24:S17-S18
14. Cohen ML. Epidemiology of drug resistance: Implications for a post-antimicrobial era. Science 1992; 257:1050-1055
15. Impacts of antibiotic-resistant bacteria: Thanks to Penicillin, He will Come Home! Washington, DC: Office of Technology Assessment, Congress; 1995. Publication OTA-H-629
16. Rubin RJ, Harrington CA, Poon A, et al. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999; 5:9-17
17. Carmeli Y, Troillet N, Karchmer AW, et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127-1132
18. Holemberg SD, Solomon SL, Blake PA. Health and economic impact of antimicrobial resistance. Rev Infect Dis 1987; 9:1065-1078
19. Phelps CE. Bug-drug resistance: Sometimes less is more. Med Care 1989; 27:194-203
20. Einarsson S, Kristjansson M, Kristinsson KG, et al. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: A case-control study. Scand J Infect Dis 1998; 30:253-256
21. Moellering RC. A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:155-157
22. Hancock RE. The role of fundamental research and biotechnology in finding solutions to the global problem of antibiotic resistance. Clin Infect Dis 1997; 24:S148-S150
23. Bax RP. Antibiotic resistance: A view from the pharmaceutical industry. Clin Infect Dis 1997; 24:S151-S153
24. Jones RN. The emergent needs for basic research, education, and surveillance of antimicrobial resistance: Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. Diag Microbiol Infect Dis 1996; 25:153-161
25. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system: Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619-1636
26. Pingleton SK, Fagon JY, Leeper KV Jr. Patient selection for clinical investigation of ventilator-associated pneumonia: Criteria for evaluating diagnostic techniques. Chest 1992; 102: 553S-556S
27. Garner JS, Jarvis WR, Emori TB, et al. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16:128-140
28. Kollef MH. Ventilator-associated pneumonia: A multivariate analysis. JAMA 1993; 270:1965-1970
29. Rubin DB, Wiener-Kronish JP, Murray JF, et al. Elevated von Willebrand factor antigen is an early phase predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990; 86:474-480
30. American College of Chest Physicians/Society of Critical Care Med Consensus Conference. Definitions for sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655
31. Meinert CL, Tonascia S. Clinical Trials: Design, conduct, and analysis. New York, NY: Oxford University Press, 1986; 194-195
32. SAS/STAT User's Guide (vol 2). Cary, NC: SAS Institute, 1990; 1071-1126
33. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993; 118:201-210
34. Rothman KJ. Analysis of crude data. In: Rothman K, ed. Modern epidemiology. Boston, MA: Little Brown, 1986; 153-174
35. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412-420
36. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-685
37. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22:387-394
38. Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156:196-200
39. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States: National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887-892
40. Coquet L, Junter GA, Jouenne T. Resistance of artificial biofilms of Pseudomonas aeruginosa to imipenem and tobramycin. J Antimicrob Chemother 1998; 42:755-760
41. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157:531-539
42. Deulofeu F, Cervello B, Capell S, et al. Predictors of mortality in patients with bacteremia: The importance of functional status. J Am Geriat Soc 1998; 46:14-18
43. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for Gramnegative bacteremia: A prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127-1133
44. Rello J, Sa-Borges M, Correa H, et al. Variations in etiology of ventilator-associated pneumonia across four treatment sites: Implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160:608-613
45. Evans RS, Classen DC, Pestotnik SL, et al. Improving empiric antibiotic selection using computer decision support. Arch Intern Med 1994; 154:878-884
46. Evans RS, Pestotnik SL, Classen DC, et al. A computerassisted management program for antibiotics and other anti-infective agents. N Engl J Med 1998; 338:232-238
47. Kollef MH, Vlasnik J, Sharpless L, et al. Scheduled rotation of antibiotic classes: A strategy to decrease the incidence of ventilator-associated pneumonia due to antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med 1997; 156:1040-1048
48. Gruson D, Hilbert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive care unit: Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med 2000 (in press)